Related Experiment Video
Updated: Jan 22, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Opioid Management in Older Adults with Chronic Kidney Disease: A Review
Montgomery T Owsiany1, Chelsea E Hawley2, Laura K Triantafylidis3
1New England Geriatric Research, Education and Clinical Center.
Abstract:
Chronic pain, a common comorbidity of chronic kidney disease, is consistently under-recognized and difficult to treat in older adults with nondialysis chronic kidney disease. Given the decreased kidney function associated with aging and chronic kidney disease, these patients are at increased risk for drug accumulation and adverse events. Emerging research has demonstrated the efficacy of opioids in chronic kidney disease patients, but research specifically focusing on older, nondialysis chronic kidney disease patients is scarce. The primary objective of this review is to determine which oral and transdermal opioids are the safest for older, nondialysis chronic kidney disease patients. We discuss the limited existing evidence on opioid prescription in older, nondialysis chronic kidney disease patients and provide recommendations for the management of oral and transdermal opioids in this patient population. Specifically, transdermal buprenorphine, transdermal fentanyl, and oral hydromorphone are the most tolerable opioids in these patients; hydrocodone, oxycodone, and methadone are useful but require careful monitoring; and tramadol, codeine, morphine, and meperidine should be avoided due to risk of accumulation and adverse events. Because older adults with nondialysis chronic kidney disease are at increased risk for adverse events, vigilant monitoring of opioid prescription is critical. Lastly, collaboration among an interprofessional clinical team can ensure safe prescription of opioids in older adults with nondialysis chronic kidney disease.
Insights
For older adults with chronic kidney disease (CKD), safe opioid use for chronic pain is crucial. Transdermal buprenorphine and fentanyl, plus oral hydromorphone, are recommended, while others require caution or avoidance.
Area of Science:
- Nephrology
- Geriatrics
- Pain Management
Background:
- Chronic pain is common in older adults with chronic kidney disease (CKD).
- Reduced kidney function in aging CKD patients increases risks of drug accumulation and adverse events.
- Opioid efficacy is emerging in CKD, but data for older, non-dialysis patients are limited.
Purpose of the Study:
- To identify the safest oral and transdermal opioids for older adults with non-dialysis CKD.
- To provide evidence-based recommendations for opioid management in this vulnerable population.
Main Methods:
- Systematic review of existing literature on opioid use in older adults with non-dialysis CKD.
- Analysis of pharmacokinetic and pharmacodynamic data relevant to impaired kidney function.
- Evaluation of adverse event profiles for various oral and transdermal opioids.
Main Results:
- Transdermal buprenorphine, transdermal fentanyl, and oral hydromorphone show the best tolerability.
- Hydrocodone, oxycodone, and methadone are viable but necessitate close monitoring.
- Tramadol, codeine, morphine, and meperidine should be avoided due to accumulation risks.
Conclusions:
- Opioid selection requires careful consideration of kidney function and patient age.
- Vigilant monitoring is essential to mitigate adverse events in older adults with CKD.
- Interprofessional collaboration ensures safe and effective opioid prescribing for chronic pain.
Related Concept Videos
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Kidney Disease III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

